Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2009

View Archived Issues

Ad2/HIF-1alpha/VP16 not effective in treating intermittent claudication

Studies show benefit of preprocedure atorvastatin loading in patients undergoing PCI

Increased malapposition seen with paclitaxel-eluting stent in acute myocardial infarction patients

Preliminary results from phase I/II study of BL-1040 myocardial implant presented

Bayer describes novel substituted tricyclic compounds for cancer treatment

Novel cytotoxic xanthone compounds claimed by Bristol-Myers Squibb

Roche claims novel NK3 receptor antagonists

Sanofi-aventis and Mitsubishi Tanabe Pharma claim novel tau protein kinase inhibitors

Novel compounds for the treatment of diabetes discovered by Kyorin and ActivX

Merck KGaA launches Lodotra in Germany

BioMS receives positive safety review for phase III multiple sclerosis trial

Osprey initiates phase Ib trial in IgA nephropathy

Phase II study reveals activity of OZ1 gene therapy in HIV patients

BioVex commences OncoVEX phase III metastatic melanoma trial

BioSante launches Elestrin in the U.S.

SC-599 well tolerated, induces protective immune responses in phase II study

Strativa provides product pipeline update for ODFS

Tobira Therapeutics initiates proof-of-concept study with TAK-652 for HIV

FDA grants orphan drug designation for Paclical in ovarian cancer

Jubilant and Orion sign drug discovery partnership

ImmuneRegen and University of Rochester to examine Homspera in lethal radiation exposure

Oxygen and Hospira sign development and commercial supply agreement for Oxycyte

Anesthetic/sedative CNS-7056 begins phase II

Sanofi-aventis to acquire BiPar Sciences

EVT-302 shows no benefit as aid to smoking cessation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.